

**Acknowledgment and Consent for Disclosure of  
18 U.S.C. §208(b)(3)  
Particular Matter Waivers**

**Name:** Steven Nissen, M.D.

**Committee:** Endocrinologic & Metabolic Drugs Advisory Committee

**Meeting Date(s):** July 1-2, 2008

I acknowledge that contingent upon public disclosure of the following financial interests submitted on my FDA Form 3410 and related to the agenda item: to discuss the role of cardiovascular assessment in the pre-approval and post-approval settings for drugs and biologics developed for the treatment of type 2 diabetes mellitus, I am eligible to receive a particular matter waiver under 18 U.S.C. §208(b)(3).

<b>Type of Interest</b>	<b>Involvement</b>	<b>Magnitude</b>
Employer's Research Contracts/Grants	2 Affected Firms	Between \$100,001 and \$300,000 per year per firm
Employer's Research Contract/Grant	1 Affected Firm	Greater than \$300,000 per year

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of the interests, the waiver is not valid.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature

\_\_\_\_\_/6/9/08\_\_\_\_\_  
Date